PBYI - Puma Biotechnology, Inc.
10.02 0.00 (0.00%)
After hours: 4:25PM EDT
| Previous Close | 10.20 |
| Open | 10.26 |
| Bid | 9.52 x 3000 |
| Ask | 10.10 x 900 |
| Day's Range | 9.51 - 10.27 |
| 52 Week Range | 9.51 - 54.20 |
| Volume | 1,608,478 |
| Avg. Volume | 1,225,182 |
| Market Cap | 386.896M |
| Beta (3Y Monthly) | 2.13 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.60 |
| Earnings Date | Aug 7, 2019 - Aug 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.86 |
- Business Wire•6 days ago
Puma Biotechnology’s Licensing Partner Knight Therapeutics Receives Regulatory Approval from Health Canada to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of Hormone Receptor Positive, HER2-Positive Early Stage Breast Cancer
LOS ANGELES-- -- Neratinib becomes the first anti-HER2 treatment to be approved in Canada, as extended adjuvant therapy for women with early stage HR-positive, HER2-positive breast cancer following adjuvant trastuzumab-based therapy. Treatment with neratinib in the approved Health Canada indication resulted in a 51% reduction in the risk of invasive disease recurrence or death at 2 years versus placebo ...
- GlobeNewswire•6 days ago
Knight Therapeutics Announces Health Canada Has Approved NERLYNX ® for Early-Stage Breast Cancer
MONTREAL, July 16, 2019 -- Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, announced today that Health Canada has approved.
- Zacks•17 days ago
Implied Volatility Surging for Puma Biotech (PBYI) Stock Options
Investors need to pay close attention to Puma Biotech (PBYI) stock based on the movements in the options market lately.
- Business Wire•19 days ago
Puma Biotechnology Presents Interim Results from the Biliary Tract Cohort of its Phase II SUMMIT Basket Trial of Neratinib at the ESMO World Congress on Gastrointestinal Cancer 2019
Puma Biotechnology, Inc. , a biopharmaceutical company, presented updated interim results from the biliary cancer cohort of SUMMIT, an ongoing Phase II basket trial examining the efficacy of neratinib in HER2-mutated cancers, at the European Society for Medical Oncology 21st World Congress on Gastrointestinal Cancer 2019, currently taking place in Barcelona, Spain.
- Zacks•20 days ago
Puma Biotech Submits sNDA for Breast Cancer Drug Nerlynx
Puma Biotech (PBYI) files an sNDA for the nod of Nerlynx in combination with Xeloda to treat patients with HER2-positive metastatic breast cancer, having failed two or more prior lines of treatments.
- Business Wire•21 days ago
Puma Biotechnology Submits a Supplemental New Drug Application to U.S. FDA for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
Puma Biotechnology, Inc. , a biopharmaceutical company, has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for neratinib in combination with capecitabine for the treatment of patients with HER2-positive metastatic breast cancer who have failed two or more prior lines of HER2-directed treatments .
- Motley Fool•22 days ago
Wall Street Has Given Up on These 3 Stocks, and That's a Huge Mistake
The market's shortsightedness has it missing the long-term upside at this biotech, logistics specialist, and pipeline company.
- Simply Wall St.•28 days ago
One Thing To Remember About The Puma Biotechnology, Inc. (NASDAQ:PBYI) Share Price
If you own shares in Puma Biotechnology, Inc. (NASDAQ:PBYI) then it's worth thinking about how it contributes to the...
- Simply Wall St.•28 days ago
Does Market Volatility Impact Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Share Price?
Anyone researching Puma Biotechnology, Inc. (NASDAQ:PBYI) might want to consider the historical volatility of the...
- Markit•last month
See what the IHS Markit Score report has to say about Puma Biotechnology Inc.
Puma Biotechnology Inc NASDAQ/NGS:PBYIView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for PBYI with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding PBYI are favorable, with net inflows of $2.33 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Simply Wall St.•last month
Did You Manage To Avoid Puma Biotechnology's (NASDAQ:PBYI) Devastating 77% Share Price Drop?
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut...
- Thomson Reuters StreetEvents•last month
Edited Transcript of PBYI earnings conference call or presentation 9-May-19 8:30pm GMT
Q1 2019 Puma Biotechnology Inc Earnings Call
- Zacks•last month
Puma Biotech (PBYI) Down 53.9% Since Last Earnings Report: Can It Rebound?
Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Motley Fool•2 months ago
Here's Why Puma Biotechnology Tumbled 53.9% in May
The most significant potential concern for the company's lone drug product arose.
- Business Wire•2 months ago
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, announced that on June 3, 2019 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 82,063 shares of Puma common stock to 15 new non-executive employees. The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
- Business Wire•2 months ago
Puma Biotechnology Presents Results from Phase III NALA Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer at the ASCO 2019 Annual Meeting
Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, announced that results from the Phase III NALA trial of PB272 (neratinib) in patients with HER2-positive metastatic breast cancer who have failed two or more prior lines of HER2-directed treatments (third-line disease) in the setting of metastatic disease, were presented at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting in Chicago. “Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial,” was presented as an oral presentation by Adam M. Brufsky, MD, PhD, Professor of Medicine, Co-Director, Comprehensive Breast Cancer Center, Magee Women’s Hospital of the University of Pittsburgh Medical Center.
- Business Wire•2 months ago
CORRECTING and REPLACING GRAPHIC Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the ASCO 2019 Annual Meeting
In the release dated June 2, 2019, please replace the PDF file with the accompanying corrected file.
- Business Wire•2 months ago
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the ASCO 2019 Annual Meeting
Puma Biotechnology, Inc. , a biopharmaceutical company, will present updated interim results from a Phase II clinical trial of Puma’s drug neratinib at the American Society of Clinical Oncology 2019 Annual Meeting in Chicago.
- Business Wire•2 months ago
Puma Biotechnology to Present at Jefferies 2019 Global Healthcare Conference
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 3:30 p.m.
- Motley Fool•2 months ago
Investors Are Right to Worry About Puma Biotechnology
A surprising number of patients discontinued treatment with the company's sole drug product in the first quarter of 2019.
